newsfilter
← Earnings
Earnings Releases·

Imricor — Q3 CY2026 Earnings Summary

  • Revenue surged 437% year-over-year to US$188k, while net loss narrowed 17% to US$2.9m; cash reserves stood at US$62.1m despite operating cash outflows increasing to US$7.3m.
  • The company confirmed a revenue inflection point for CY2026 driven by the U.S. commercial launch of NorthStar, with two major hospital customers secured and additional revenue from the NorthStar sale to Children's Medical Center Dallas recognized in Q4.
  • Strategic progress includes FDA 510(k) clearances for pediatric label expansions on NorthStar and Vision-MR, completion of 14 of 15 U.S. platform submissions, and the launch of Imricor Finance to remove capital barriers for hospital adoption.
  • Future outlook focuses on scaling the U.S. commercial organization, converting the hospital pipeline, and completing the VISABL-AFL clinical trial and FDA pre-approval inspection for the Vision-MR Ablation Catheter.